Summary: Although previous studies have reported successful cardiac tissue ablation with high-intensity focused ultrasound using a mechanism of thermal necrosis, our study is the first to report targeted tissue fractionation and creation of an atrial septal defect in a beating heart using extracardiac ultrasound through controlled acoustic cavitation, or histotripsy. In an open-chest canine model, histotripsy generated demarcated tissue destruction through the Correspondence to The Editors, Circulation Editorial Office,
Summary: Platelet adhesion and activation are key events contributing to arterial thrombosis in disease states such as atherosclerosis, the leading cause of morbidity and mortality in industrialized countries. Although our current therapeutic armamentarium for preventing and treating complications associated with atherothrombosis has yielded promising results, there remains an urgent need for more effective drugs and better monitoring of treatment modalities. To expedite this process, it is necessary to develop animal models that more accurately recapitulate the human response to antiplatelet agents. In the present report, we demonstrate how mice bearing a genetically modified form of VWF can serve as a biological platform for predicting the in vivo efficacy of such therapies by enabling human platelet thrombus formation at sites of vascular injury, an event critically reliant on adhesion receptors, secretory products, and activation pathways known to contribute to this process in atherosclerotic coronary arteries (ie, ␣IIb␤3, ADP, and P2Y 12 ). This is further supported by the ability of the Food and Drug Administration-approved ␣IIb␤3 blockers abciximab, eptifibatide, and tirofiban to effectively limit human but not mouse platelet-mediated clot formation at doses recommended by the American College of Cardiology/American Heart Association for percutaneous coronary intervention. However, the most beneficial aspect of this model may be its ability to ascertain the inhibitory capacity of antiplatelet agents after administration to patients. As such, it may aid in correlating values obtained by function monitoring devices with the thrombogenic capacity of platelets when exposed to sites of vascular damage in a living animal, thus providing new insights into this highly debated area of clinical research.
Conclusions:
The ability of ␣IIb␤3 and P2Y 12 inhibitors to limit human platelet clot formation at doses recommended by the American College of Cardiology/American Heart Association suggests that VWF R1326H mutant mice can serve as both a pharmacodynamic and a functional response biomarker, attributes essential for not only expediting drug development but also designing clinical studies. 1 
Cardiac Arrhythmogenic Remodeling in a Rat Model of Long-Term Intensive Exercise Training
Summary: Despite the well-recognized benefits of exercise training in healthy individuals and in patients with cardiovascular disease, increasing evidence has suggested that long-term high-level exercise practice (as in athletic contexts) can increase the risk of developing cardiac arrhythmias. Both atrial tachyarrhythmias (particularly atrial fibrillation) and (much more rarely) potentially malignant ventricular arrhythmias have been associated with sustained high-level endurance training. There have been debates about whether these arrhythmias are due to undiagnosed underlying cardiac arrhythmogenic diseases, with long-term exercise being a triggering factor, or whether high-intensity long-term exercise can actually be a primary cause of arrhythmia susceptibility. To provide insights into the ability of sustained high-level exercise to cause arrhythmogenic cardiac remodeling, we applied an experimental model in which male rats were trained to run vigorously 1 hour daily for 16 weeks and compared them with a parallel group of sedentary control rats. We found that intense long-term exercise induced morphological and functional changes characteristic of the "athlete's heart" as described in humans, along with extracellular matrix changes and fibrosis affecting all chambers except the left ventricle. Ventricular arrhythmia susceptibility to programmed electric stimulation was enhanced in exercise-trained rats. The fibrotic changes caused by 16 weeks of vigorous exercise training were reversible within several weeks of exercise cessation. These results, if confirmed in humans, suggest that long-term vigorous endurance exercise training may cause cardiac remodeling that serves as a substrate for arrhythmia vulnerability. Our findings may have important potential implications for arrhythmia risk assessment and management in individuals performing high-level exercise training.
Conclusions:
In this animal model, we documented cardiac fibrosis after long-term intensive exercise training, together with changes in ventricular function and increased arrhythmia inducibility. If our findings are confirmed in humans, the results would support the notion that long-term vigorous endurance exercise training may in some cases promote adverse remodeling and produce a substrate for cardiac arrhythmias. 2 targeted region of atrial septum with no insult to other cardiac structures and modest damage to adjacent septal tissue. Continued advances in probe design and motion-tracking algorithms should minimize this collateral damage. Although further studies are necessary to determine the efficacy and safety of this technology in an intact neonatal animal model, this initial report provides the first evidence that histotripsy may be a useful, minimally invasive clinical tool to create atrial septal defects or other intracardiac communications in infants with congenital heart diseases.
Conclusions: Under real-time ultrasound guidance, atrial septal defects were successfully created with extracardiac histotripsy in a live canine model. Although further studies in an intact animal model are needed, these results provide promise of histotripsy becoming a valuable clinical tool. 3 
Marked Variability in Susceptibility to Ventricular Fibrillation in an Experimental Commotio Cordis Model
Summary: The data reported in this article demonstrate for the first time that an individual susceptibility to commotio cordis exists. Whether individuals are more or less susceptible to chest wall blow-induced ventricular fibrillation has been a clinical question for quite some time, and individual susceptibility may partially explain the rarity of the condition. Yet, despite its rarity, commotio cordis is the second leading cause of sudden cardiac death on the playing field for young athletes. It also is of major concern to parents, coaches, and organizations such as US Lacrosse and Little League Baseball. These data also have clinical implications for the decision of whether return to sports for individuals who have survived a commotio cordis event is wise.
Conclusions: Swine display a wide range of individual vulnerability to ventricular fibrillation triggered by chest wall impact, with a distinct minority being uniquely susceptible. Mild abnormalities in cardiac depolarization and repolarization might underlie this susceptibility. Such individual susceptibility may also be present in humans and contribute to the rarity of commotio cordis. 4 
Intracoronary Optical Coherence Tomography and Histology at 1 Month and 2, 3, and 4 Years After Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model: An Attempt to Decipher the Human Optical Coherence Tomography Images in the ABSORB Trial
Summary: Alterations of the reflectance characteristics of the everolimus-eluting bioresorbable vascular scaffold struts have been reported in humans. However, in the absence of histology, the interpretation of the appearances of the struts by optical coherence tomography (OCT) remains speculative. In the present animal study, the bioresorbable vascular scaffold (3.0ϫ12.0 mm) was implanted in the coronary arteries of pigs that underwent OCT and then were examined by histology immediately or at 28 days or 2, 3, or 4 years after implantation. To assess the biodegradation, gel permeation chromatography was performed. At 2 years, OCT showed that 80.4% of the strut sites had a box-shaped appearance. On histology, these structures were composed of proteoglycan. By gel permeation chromatography, the polymeric material of bioresorbable vascular scaffold was no longer quantifiable, suggesting complete bioresorption. At 3 years, by OCT, most struts showed dissolved appearances (dissolved black, 43.7%; dissolved bright, 34.8%). Histology showed connective tissue cells within a proteoglycan-rich matrix, signifying the beginning of the integration process. At 4 years, only a few struts were recognizable by OCT, and on histology, struts indiscernible by OCT are also minimally detectable, which suggests complete integration. In summary, despite their defined appearance by OCT, struts at 2 years were largely bioresorbed, and at 4 years, struts indiscernible by OCT corresponded well to the completely integrated struts. OCT might be more sensitive to assess the integration process rather than the polymer alteration. This animal study will potentially serve as a guide for interpretation of OCT after bioresorbable vascular scaffold implantation in the clinical setting.
Conclusions: Struts that are still discernible by OCT at 2 years are compatible with largely bioresorbed struts, as demonstrated by histological and gel permeation chromatography analysis. At 3 and 4 years, both OCT and histology confirm complete integration of the struts into the arterial wall. 5 
Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema
Summary: The lymphatic vascular system is crucial for the regulation of tissue fluid homeostasis, fat metabolism, and elicitation of immune responses. Lymphatic dysfunction, either resulting from gene alterations or secondary to damage to the lymph vessels, may lead to lymphedema, a debilitating condition characterized by chronic tissue edema, impaired immunity, and accumulation of subcutaneous fat. Lymphedema is a common and incurable problem. Interestingly, during recent years, application of lymphangiogenic growth factors has been shown to induce lymphangiogenesis and to reduce tissue edema in small animal models. The aim of the present study was to evaluate the potential of growth factor therapy in a clinically relevant novel large animal model. Lymphedema patients have recurrent infections and thus would benefit from both functional lymphatic vessels and lymph nodes. In an attempt to restore the lymphatic anatomy, we combined growth factor therapy with lymph node transfer. Interestingly the lymph nodes transduced with vascular endothelial growth factors (C and D) survived and formed both afferent and efferent connections with the preexisting lymphatic vessel network, whereas the control vector-treated nodes regressed. We compared the effect of 2 different endothelial growth factors to select the best candidate for the clinical trials. Combining autologous lymph node transfer and therapeutic growth factors provides a promising tool for the curative treatment of lymphatic vessel dysfunction after infection, surgery, or radiation therapy.
Conclusions: These results show that growth factor gene therapy coupled with lymph node transfer can be used to repair damaged lymphatic networks in a large animal model and provide a basis for future clinical trials of the treatment of lymphedema. 6 
Downregulation of Kv7.4 Channel Activity in Primary and Secondary Hypertension
Summary: Hypertension is a major risk factor for a number of cardiovascular diseases and is the leading cause of mortality worldwide. Hypertension is characterized by an increase in peripheral resistance and is associated with remodeling of the blood vessel architecture, which contributes to the maintenance of elevated blood pressure in the longer term. Recently, voltage-dependent potassium channels encoded by the KCNQ gene family (Kv7.1 through Kv7.5) have been identified in rodent and human vascular smooth muscle, in which they are important regulators of the membrane potential and hence vascular contractility. The present study shows that in normotensive rats and mice, structurally different Kv7 activators relaxed mesenteric resistance vessels and thoracic aorta and improved coronary perfusion considerably. Strikingly, the vasorelaxant effects of these agents were markedly attenuated in tissues from spontaneously hypertensive rats and angiotensin II-infused hypertensive mice, and the effect on coronary perfusion was negligible. These impaired functional responses were associated with a downregulation of KCNQ4 gene expression and reduced production of Kv7.4 protein. Downregulation of KCNQ4 and the loss of this antispasmogenic mechanism appear to be a common feature of hypertensive blood vessels, which provides considerable new insight into the pathogenesis of hypertension. Strategies for restoring KCNQ4 could be therapeutically beneficial.
Conclusion:
In 2 different rat and mouse models of hypertension, the functional impact of Kv7 channels was dramatically downregulated. 7
Ca

2؉ -Related Signaling and Protein Phosphorylation Abnormalities Play Central Roles in a New Experimental Model of Electric Storm
Summary: Electrical storm (ES), characterized by recurrent ventricular tachycardia/fibrillation, is an increasing problem among implantable cardioverter-defibrillator patients. Despite acute cessation of ES with medical therapy and/or catheter ablation, the early mortality (within a few months of ES) is high and often nonsudden, involving progressive heart failure in particular. Underlying mechanisms are unknown. Defective Ca 2ϩ handling is central to the pathogenesis of heart failure. Changes in phosphorylation of L-type Ca 2ϩ channels, sarcoplasmic reticulum Ca 2ϩ -release channel ryanodine receptors, and the sarcoplasmic reticulum Ca 2ϩ uptake regulator protein phospholamban are linked to heart failure-related mechanical dysfunction and arrhythmogenic afterdepolarizations. To study the molecular basis of ES-related cardiac deterioration, we studied rabbits with chronic complete atrioventricular block equipped with implantable cardioverter-defibrillators. They developed QT prolongation and implantable cardioverter-defibrillatordetected ventricular fibrillation episodes, with ES (defined as clustered, frequently recurrent ventricular fibrillation episodes) occurring in Ϸ50%. ES rabbits showed left ventricular function deterioration, along with striking activation of the Ca 2ϩ -sensitive phosphorylating enzyme Ca 2ϩ /calmodulin-dependent protein kinase II (CaMKII) and enhanced protein phosphatase expression. These alterations produced important changes in phosphorylation patterns, notably hyperphosphorylation of L-type Ca 2ϩ channels and ryanodine receptors and dephosphorylation of phospholamban, which could explain arrhythmias and impaired contractility. Repeated ventricular fibrillation induction/defibrillation with implantable cardioverterdefibrillator shocks in control rabbits reproduced ES-related changes in CaMKII and phospholamban phosphorylation. Infusion of the calmodulin antagonist W-7 suppressed ventricular tachycardia/ ventricular fibrillation episodes and rescued left ventricular dysfunction in ES rabbits, indicating a central pathophysiological role of CaMKII activation. These results strongly support the notion that CaMKII activation and Ca 2ϩ -handling abnormalities resulting from ES events might be responsible for negative outcomes and suggest that interventions targeting the Ca 2ϩ /calmodulin/CaMKII system might provide benefits in ES patients. Summary: Ischemia-reperfusion is still the most common cause for organ dysfunction and failure after myocardial infarction, hemorrhagic shock, and transplantation. Neutrophil recruitment to the reperfused tissue as well as postischemic microvascular leakage are critical for the pathogenesis of ischemia-reperfusion injury. Although plasminogen activators such as recombinant urokinase-type plasminogen activator (uPA) are used therapeutically for the activation of the fibrinolytic system in thrombembolic events, endogenously produced uPA has recently been implicated in the progression of ischemia-reperfusion injury. The underlying mechanisms remain poorly understood. In the present study, we found that endogenous uPA promotes intravascular accumulation and paracellular transmigration of neutrophils to the reperfused tissue independently of the uPA receptor via the integrin CD11b/Mac-1, which serves as an alternative receptor of uPA. Endothelial-presented uPA is thought to promote leukocyte intravascular adherence via its nonproteolytic properties whereas leukocyte uPA is thought to trigger the subsequent paracellular transmigration of neutrophils. We further show that postischemic microvascular leakage is mediated by uPA in a uPA receptor-dependent manner. Pharmacological inhibition of uPA interferes with these inflammatory events and attenuates postischemic neutrophil responses, microvascular leakage, and tissue injury. Because fibrinolysis is known to be largely dependent on the plasminogen-activating action of endogenous tissue-plasminogen activator and clinical trials did not provide any evidence of prothrombotic side effects relative to uPA inhibitors, pharmacological blockade of endogenously released uPA might emerge as a feasible strategy for the prevention of ischemia-reperfusion injury.
Conclusions
Conclusions: Our data suggest that endothelial uPA promotes intravascular adherence, whereas leukocyte uPA facilitates the subsequent paracellular transmigration of neutrophils during ischemiareperfusion. This process is regulated via CD11b/Mac-1, and does not require uPAR. Pharmacological blockade of uPA interferes with these events and effectively attenuates postischemic tissue injury. 9 
Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension
Summary: Pulmonary arterial hypertension is a vascular disorder associated with significant morbidity and mortality. Its histological hallmark is the presence of plexiform lesions. The genesis and hemodynamic effects of the lesions, however, remain unknown. To date, no small animal model of pulmonary hypertension exists that rigorously mimics the plexiform lesions found in patients with idiopathic pulmonary arterial hypertension. This study demonstrates that plexiform lesions develop in an experimental rat model of severe pulmonary arterial hypertension. In addition, this model closely mimics the pathophysiology and other occlusive vascular lesions of human pulmonary arterial hypertension. This model will facilitate investigations of the pathogenesis of pulmonary arterial hypertension, lead to better understanding of this vascular disorder, and have value for rigorous preclinical drug evaluations.
Conclusions: Severe, sustained pulmonary hypertension in a very late stage of the Sugen 5416/hypoxia/normoxia-exposed rat is accompanied by the formation of lesions that are indistinguishable from the pulmonary arteriopathy of human pulmonary arterial hypertension. This unique model provides a new and rigorous approach for investigating the genesis, hemodynamic effects, and reversibility of plexiform and other occlusive lesions in pulmonary arterial hypertension. 10 
Selective Molecular Potassium Channel Blockade Prevents Atrial Fibrillation
Summary: Atrial fibrillation is the most common arrhythmia found in clinical practice, affecting 2 to 5 million people in the United States and several million more worldwide. The presence of atrial fibrillation substantially increases individual risk of stroke, heart failure, and death. A principal limitation to clinical practice is the lack of safe, effective therapies for this pervasive arrhythmia. We previously reported a gene-painting method capable of 100% transmural gene transfer to all parts of the atria accessible from an open-chest pericardium approach. In the present report, we used this method to transduce the atria with KCNH2-G628S, a mutation that blocks the rapid component of the delayed rectifier potassium current. This current is also blocked by class III antiarrhythmic drugs, but those drugs affect atrial and ventricular myocytes alike. The painting method is specific to atrial myocytes. We found that KCNH2-G628S gene transfer prolonged atrial action potential and prevented atrial fibrillation. This effect correlated with the time course of transgene expression. The method should be directly applicable to the problem of postoperative atrial fibrillation. With modifications to increase duration of gene expression and to reduce the invasive nature of delivery, the method should also be applicable to general atrial fibrillation. Formal preclinical testing is required before clinical investigation.
Conclusions: Gene therapy with KCNH2-G628S eliminated atrial fibrillation by prolonging atrial action potential duration. The effect duration correlated with transgene expression. 11
Inhaled Nitric Oxide Improves Outcomes After Successful Cardiopulmonary Resuscitation in Mice
Summary: Sudden cardiac arrest is one of the leading causes of death worldwide. Despite advances in resuscitation techniques, Ͻ8% of the 300 000 adults who experience cardiac arrest in the United States each year survive to hospital discharge, and up to 60% of survivors have long-lasting neurological deficits. Although therapeutic hypothermia has proven effective in clinical studies, no pharmacological agent is available to improve outcome from cardiac arrest. Although originally developed as a selective pulmonary vasodilator, inhaled nitric oxide (NO) has been shown to have systemic effects in a variety of preclinical and clinical studies without causing systemic vasodilation. In the present study, we found that breathing a low concentration of NO starting 1 hour after successful cardiopulmonary resuscitation for 23 hours markedly improves long-term neurological and cardiac outcomes and survival in mice subjected to cardiac arrest and cardiopulmonary resuscitation. The ability of NO breathing to improve outcomes after cardiac arrest when begun after cardiopulmonary resuscitation, if extrapolated to human beings, makes inhaled NO a practical therapeutic approach that can be initiated after patients are transferred to a hospital. Furthermore, because inhaled NO does not cause systemic hypotension, in contrast to systemic NO donors, it is uniquely suited for the treatment of post-cardiac arrest patients in whom blood pressure is often unstable. We anticipate that the established safety profile of NO inhalation will enable the rapid translation of findings in animal models to patients suffering from the post-cardiac arrest syndrome.
Conclusions:
These results suggest that NO inhalation after cardiac arrest and successful CPR improves outcome via soluble guanylate cyclase-dependent mechanisms. 12 
Remote Ischemic Preconditioning Protects the Brain Against Injury After Hypothermic Circulatory Arrest
Summary: In the repair of complex congenital heart defects or in surgery of the aortic arch, normal circulation may be temporarily halted to ensure a clean bloodless operation field. The brain is the organ most vulnerable to ischemic injury during this period of hypothermic circulatory arrest (HCA), and the mortality and morbidity of these procedures today consists largely of neurological complications. Ischemic preconditioning, a plausible neuroprotective strategy, describes a concept whereby brief exposure to ischemia, in a dose below the threshold for tissue injury, provides robust protection against the injurious effects of a subsequent more severe insult. In remote ischemic preconditioning, intermittent ischemia is induced in a nontarget tissue such as the limb, and the signal is thought to spread systemically by a mechanism that includes activation of the autonomic nervous system and as yet unidentified humoral mediators. Our study demonstrates that the neuroprotective effect after a series of blood pressure cuff inflations of the hind leg before HCA in a surviving porcine model was associated with a significant reduction in some important markers of neurological injury, accelerated neurological recovery and mitigated cerebral histopathologic findings. Remote ischemic preconditioning might be neuroprotective in patients undergoing surgery with HCA and improve long-term outcomes. If intermittent limb occlusions are shown consistently to reduce neurological injury during complex cardiac surgery with HCA, clinical implications can be very important. The intervention is practical, cost effective, and noninvasive. Clinical trials to further investigate its applications are warranted.
Conclusions: These data demonstrate that remote ischemic preconditioning (RIPC) protects the brain against HCA-induced injury, resulting in accelerated recovery of neurological function. RIPC might be neuroprotective in patients undergoing surgery with HCA and improve long-term outcomes. Clinical trials to test this hypothesis are warranted. 13 
Delayed Postconditioning in the Mouse Heart In Vivo
Summary: The major finding of this study is that delayed postconditioning allows infarct size to be reduced in the mouse heart in vivo. This observation emphasizes the fact that the cardioprotection window for postconditioning is wider than initially reported. Such information may be of major importance for clinical applications. Manual thrombectomy, in addition to primary percutaneous coronary intervention, has been shown to improve microvascular reperfusion, with a lower mortality at 1-year follow-up. Unfortunately, routine use of mechanical thrombectomy during primary percutaneous coronary intervention increases procedure time and precludes the application of angioplasty postconditioning in the 1 minute of reflow. Confirmation of the existence of a longer cardioprotection window by postconditioning in a range of animal myocardial infarction models, including larger animals, may justify new clinical trials combining manual thrombectomy and angioplasty postconditioning in patients with acute myocardial infarction in accordance with the recently published recommendations for investigating novel cardioprotective strategies. In addition, demonstration of delayed postconditioning may also be of interest in patients with incomplete reperfusion at hospital admission in whom episodes of brief ischemia/reperfusion may be performed during the percutaneous coronary intervention to further reduce infarct size. However, the translation of cardioprotection from the experiment to the clinic is not obvious, because species differences, age, comorbidities, cotreatments, and the status of the coronary circulation may interfere with postconditioning. We think that our data, which demonstrate the existence of a longer cardioprotection window, are conceptually relevant for a clinical application and make the case for a pharmacological strategy.
Conclusions: This study in our in vivo mouse model of myocardial ischemia/reperfusion shows for the first time that delaying the intervention of postconditioning to 30 minutes does not abrogate the cardioprotective effect of postconditioning. This finding provides evidence that the time window of protection afforded by postconditioning may be larger than initially reported. 14 
Rhesus Macaques Develop Metabolic Syndrome With Reversible Vascular Dysfunction Responsive to Pioglitazone
Summary: The metabolic syndrome (MetS) is a constellation of clinical features that include central obesity, hypertension, atherogenic dyslipidemia, and insulin resistance and is clinically important both because of its prevalence and because it increases the risk for cardiovascular disease and type 2 diabetes mellitus (T2D). However, the concept remains controversial, and there is a need for better understanding of how MetS predisposes to cardiovascular disease and T2D. Here, we devised and implemented a strategy to establish a spontaneous nonhuman primates model of MetS, investigated the emergence of MetS in relation to vascular dysfunction, and determined the response to an established pharmacological treatment for diabetes mellitus. By identifying MetS-predisposed animals among 408 rhesus monkeys of 12.7 years age and acclimating them to standardized laboratory conditions for 18 months, we established a nonhuman primates model of spontaneous MetS that faithfully reproduced salient features of human MetS. During the transition from pre-MetS to onset MetS, individual components of MetS emerged together, indicating common shared underlying processes rather than simultaneous occurrence of independent risk factors. Importantly, vascular dysfunction (60% impairment of flowmediated dilation of brachial artery) tracked with development of MetS. Pioglitazone, a peroxisome proliferator-activated receptor ␥ agonist, reversibly improved atherogenic dyslipidemia and insulin resistance and fully restored flow-mediated dilation with persistent effect, suggesting the benefit for early treatment of MetS before frank T2D develops. This unique nonhuman primate model of MetS, as demonstrated here, should be highly valuable in mechanistic and translational studies on the pathogenesis of MetS in relation to cardiovascular disease and T2D.
Conclusions: Coemergence of metabolic and cardiovascular components during MetS progression and complete normalization of vascular dysfunction with peroxisome proliferator-activated receptor ␥ agonists suggest shared underlying mechanisms rather than separate processes, arguing for the benefit of early intervention of MetS components. Predictive nonhuman primate (NHP) models of MetS should be highly valuable in mechanistic and translational studies on the pathogenesis of MetS in relation to cardiovascular disease and diabetes mellitus. 15 
Novel Chemical Suppressors of Long QT Syndrome Identified by an In Vivo Functional Screen
Summary: Long QT syndrome (LQTS), caused by either genetic defects or pharmaceutical agents, carries a risk of sudden death. Despite significant medical advances in our understanding of the molecular and cellular mechanisms of these syndromes, there are still no therapies that directly address the underlying physiological problem of prolonged repolarization time. In this study, we used a zebrafish model of LQTS type 2 that harbors a mutation in the KCNH2 gene. The diminutive physical size of zebrafish enabled a small-molecule screen for compounds that rescued the LQTS phenotype. We identified 2 compounds, 2-methoxy-N-(4-methylphenyl) benzamide and the steroid flurandrenolide, that reproducibly rescued the zebrafish LQT mutant in a dose-dependent fashion by shortening the prolonged ventricular action potentials. Neither of these compounds exerts their effects by rescuing the ion channel trafficking defect that results from the zebrafish LQTS mutation. We show that flurandrenolide acts through the glucocorticoid receptor to suppress LQTS in this model. This study highlights the power of using a nonbiased functional screen to identify compounds that may prove to be new tools for the study of cardiac electrophysiology and may lead to novel therapeutics for human LQTS patients.
Conclusions: Using a zebrafish model of LQT type 2 syndrome in a high-throughput chemical screen, we have identified 2 compounds, flurandrenolide and the novel compound 2-MMB, as small molecules that rescue the zebrafish LQT type 2 syndrome by shortening the ventricular action potential duration. We provide evidence that flurandrenolide functions via the glucocorticoid receptor-mediated pathway. These 2 molecules and future discoveries from this screen should yield novel tools for the study of cardiac electrophysiology and may lead to novel therapeutics for human LQT patients. 16 
Uncoupled Cardiac Nitric Oxide Synthase Mediates Diastolic Dysfunction
Summary: Heart failure with preserved ejection fraction as a result of diastolic dysfunction accounts for significant morbidity, mortality, and healthcare expenditures. Although many proven therapies exist for heart failure patients with reduced ejection fraction, specific treatments for diastolic dysfunction are lacking. In the vasculature, hypertension and activation of the renin-angiotensin system lead to reduced vascular nitric oxide (NO), in part because NO synthase (NOS) becomes uncoupled. This dysfunctional state of NOS is characterized by oxidative depletion of its cofactor tetrahydrobiopterin (BH 4 ), which leads to production of superoxide instead of NO. NO and NOS are also modulators of cardiac relaxation. We hypothesized that hypertension or activation of the renin-angiotensin system leads to cardiac NOS uncoupling and diastolic dysfunction. Using a mouse model of mild hypertension to mimic the most common risk factor for diastolic dysfunction in humans, we showed that isolated impaired cardiac relaxation is associated with uncoupled NOS. Local cardiac activation of the renin-angiotensin system demonstrated that cardiac oxidation was sufficient to cause diastolic dysfunction without hypertension. Diastolic dysfunction could be treated or prevented by oral administration of BH 4 , which recoupled cardiac NOS. These results suggest that BH 4 may be of value in the treatment of diastolic dysfunction.
Conclusions: Cardiac oxidation, independently of vascular changes, can lead to uncoupled cardiac NOS and diastolic dysfunction. BH 4 may represent a possible treatment for diastolic dysfunction. 17
Smooth Muscle-Specific Deletion of Nitric Oxide-Sensitive Guanylyl Cyclase Is Sufficient to Induce Hypertension in Mice
Summary: Hypertension is one of the most prevalent risk factors in the Western world and contributes to a variety of cardiovascular diseases, including coronary heart disease or heart failure. Many different mechanisms have been suggested to contribute to the development of elevated blood pressure. One model to explain the development of hypertension is based on intrinsic changes in the kidney leading to altered sodium handling, volume expansion, and elevated vascular resistance. However, increased vascular resistance may also be the consequence of changes in vessel tone and morphology. Only a few studies have investigated the possibility that hypertension may result solely from changes in the vascular system. Vessel tone and thus blood pressure are known to be regulated by the nitric oxide (NO)/cGMP signaling cascade, in part through shearmediated production of NO in the endothelium and subsequent activation of NO-sensitive guanylyl cyclase (NO-GC) to induce vessel relaxation. We have previously shown that mice lacking NO-GC are hypertensive; however, global deletion of NO-GC in mice does not allow for the identification of the cell and/or tissue type responsible for the resultant elevated blood pressure. In this study, we developed a mouse model in which NO-GC was specifically deleted in smooth muscle cells of adult mice using a tamoxifeninducible system. Here, we show that these animals gradually develop hypertension within 3 to 4 weeks that is paralleled by a loss of NO sensitivity of smooth muscle cells. In summary, our data provide evidence that deletion of NO-GC solely in vascular smooth muscle is sufficient to cause hypertension.
Conclusions: We generated a model in which the development of hypertension can be visualized over time by deletion of a single gene in smooth muscle cells. In sum, our data provide evidence that deletion of NO-GC solely in smooth muscle is sufficient to cause hypertension. 18 
Nitric Oxide-Dependent Bone Marrow Progenitor Mobilization by Carbon Monoxide Enhances Endothelial Repair After Vascular Injury
Summary: Carbon monoxide (CO) is recognized as a potent therapeutic molecule at low, nontoxic doses. CO is in phase II clinical trials to improve kidney function after transplant of a kidney allograft. Inhaled CO is known to block intimal hyperplasia after balloon angioplasty. The data presented here offer continued insight into a potential therapeutic adjuvant involving treatment with CO gas 
Mechanisms of Atrial Tachyarrhythmias Associated With Coronary Artery Occlusion in a Chronic Canine Model
Summary: Coronary artery disease is an important risk factor for atrial fibrillation (AF), but the underlying mechanisms have not been explored extensively. In this study, we considered the hypothesis that chronic obstructive coronary artery disease can create a substrate for AF initiation and maintenance by altering atrial properties. In a chronic dog model, we ligated a small coronary artery that provides blood flow only to a portion of the right atrial free wall. After coronary artery ligation, dogs showed increased occurrence of spontaneous atrial ectopy and atrial tachyarrhythmias, along with a substrate for AF maintenance. Cellular studies showed that spontaneous ectopy was related to triggered activity caused by Ca 2ϩ -handling abnormalities, including enhanced Na ϩ -Ca 2ϩ exchange current and spontaneous quantal Ca 2ϩ releases (sparks) occurring during adrenergically driven Ca 2ϩ loading. AF maintenance was related to stable rotors located in the border zone of the atrial infarction resulting from coronary artery occlusion. Local conduction abnormalities in the heterogeneous border zone of the infarction provided the substrate for reentry. These results show that chronic occlusive disease of coronary arteries supplying atrial tissue produces atrial abnormalities that provide both triggers for AF initiation and a substrate for AF maintenance. They indicate a potential mechanism for the observed association between coronary artery disease and AF. These mechanistic concepts may be useful for understanding AF pathophysiology and developing new mechanismbased approaches to patient-specific therapeutics.
Conclusions: Chronic atrial ischemia/infarction creates substrates for both spontaneous ectopy (Ca 2ϩ -release events, increased Na ϩ -Ca 2ϩ exchange current) and sustained reentry (conduction abnormalities that anchor reentry). Thus, chronic atrial infarction in dogs promotes both AF triggers and the substrate for AF maintenance. These results provide novel insights into potential AF mechanisms in patients with coronary artery disease. 20
H11 Kinase/Heat Shock Protein 22 Deletion Impairs Both Nuclear and Mitochondrial Functions of STAT3 and Accelerates the Transition Into Heart Failure on Cardiac Overload
Summary: Cardiac overload represents a major cause of heart failure and triggers the activation of multiple stress-activated pathways, including the expression of the heat shock protein H11 kinase/Hsp22 (Hsp22). The objective of the present study was to determine the specific function of Hsp22 in a context of overload. This goal was achieved by generating a knockout mouse model of Hsp22 deletion. We show that, under pressure overload generated by aortic constriction, deletion of Hsp22 accelerates the transition into heart failure and increases mortality. Specifically, Hsp22 represents a necessary and previously undescribed activator of the stress-regulated transcription factor STAT3. We also illustrate that Hsp22 couples the activity of STAT3 as a transcription factor, together with its novel function as an activator of mitochondrial respiration. Therefore, Hsp22 represents a novel mode of cardiac stress response by combining the adaptation of gene expression and that of mitochondrial respiration.
Conclusions: This study found that Hsp22 represents a previously undescribed activator of both nuclear and mitochondrial functions of STAT3, and its deletion in the context of pressure overload in vivo accelerates the transition into heart failure and increases mortality. 21
Phosphorylation of Vasodilator-Stimulated Phosphoprotein Prevents Platelet-Neutrophil Complex Formation and Dampens Myocardial Ischemia-Reperfusion Injury
Summary: The formation of platelet-neutrophil complexes has significant impact on the extent of inflammatory and ischemic tissue injury. In the present study, we demonstrate that vasodilatorstimulated phosphoprotein, a crucial cytoskeletal protein involved in platelet activation, influences the formation of these plateletneutrophil complexes. The phosphorylation of vasodilatorstimulated phosphoprotein during the reperfusion phase, achieved through the administration of prostaglandin E 1 or atrial natriuretic peptide, significantly attenuates the formation of platelet-neutrophil complexes and as a result reduces the extent of myocardial ischemia-reperfusion injury. This implies that phosphorylation of vasodilator-stimulated phosphoprotein during reperfusion has cardioprotective potential and could be pursued as a future strategy to reduce myocardial reperfusion injury.
Conclusion:
Previously unappreciated, the phosphorylation of vasodilator-stimulated phosphoprotein performs a key function for the formation of platelet-neutrophil complexes that is crucially important for the extent of myocardial ischemia-reperfusion injury. 22
Reversal of Hyperlipidemia With a Genetic Switch Favorably Affects the Content and Inflammatory State of Macrophages in Atherosclerotic Plaques
Summary: The ultimate cure for atherosclerosis would be the regression of arterial plaques. Discovery research toward this goal has been hampered by limited and sometimes cumbersome animal models. The Reversa mouse combines a standard model of human atherosclerosis, the hyperlipidemic low-density lipoprotein receptordeficient mouse, with a genetic switch that electively shuts off low-density lipoprotein production. In the present study, arterial plaques were allowed to develop in Reversa mice to a stage mimicking advanced human coronary artery disease, and then the elevated low-density lipoprotein level was severely reduced, thereby simulating aggressive lipid management. The major findings after such lipid reduction were decreases in the content and inflammatory state of the central cell of plaques, macrophages, with the change in total plaque size more modest because of compensatory increases in collagen content. Summary: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by stress-or exerciseinduced polymorphic ventricular tachycardia, frequently leading to sudden cardiac death. A considerable body of evidence accumulated over recent years suggests that mutation-linked cardiac ryanodine receptor defects cause Ca 2ϩ leak from sarcoplasmic reticulum, which triggers delayed afterdepolarization and ultimately leads to CPVT. However, the underlying mechanism, by which a single mutation in such a large molecule causes drastic effects on the channel function, remains unresolved. Here we report that introduction of a human CPVT mutation S2246L (serine to leucine mutation at residue 2246) into the mouse ryanodine receptor induces aberrant activation of channel gating by forming an abnormally tight domaindomain interaction between the S2246L mutable domain (residue 2232-2266) and the K201-binding domain (residue 2114 -2149). This produces more global conformational change in the ryanodine receptor: an aberrant domain unzipping between the N-terminal (residue 1-600) domain and the central (residue 2000 -2500) domain owing to the allosteric conformational coupling mechanism. The coupled conformational changes in these local and global interdomain interactions trigger diastolic Ca 2ϩ release and lethal arrhythmia. Pharmacological correction of the defective interdomain interactions can stop the aberrant Ca 2ϩ release and lethal arrhythmia. These results provide a new pathogenic mechanism of CPVT and a novel therapeutic strategy against CPVT.
Conclusions:
The catecholaminergic polymorphic ventricular tachycardia-linked mutation of RyR2, S2246L, causes an abnormally tight local subdomain-subdomain interaction within the central domain involving the mutation site, which induces defective interaction between the N-terminal and central domains. This results in an erroneous activation of Ca 2ϩ channel in a diastolic state reflecting on the increased Ca 2ϩ spark frequency, which then leads to lethal arrhythmia. 24 
The Alternative Pathway Is Critical for Pathogenic Complement Activation in Endotoxin-and Diet-Induced Atherosclerosis in Low-Density Lipoprotein ReceptorDeficient Mice
Summary: Previous experiments in animals have suggested that the early components of the classical and lectin complement pathways may have protective effects against the development of atherosclerosis. In this study, we have addressed the role of the alternative pathway by crossing the low-density-lipoprotein receptor-deficient mouse model of atherosclerosis (Ldlr -/-) with mice that lack complement factor B (Bf -/-), the initiator of the alternative pathway. Under 2 different proatherogenic conditions, administration of lipopolysaccharide and high-fat diet, Bf -/-/Ldlr -/-mice showed markedly reduced atherosclerotic lesion formation compared with Ldlr -/-mice. The protective effects of factor B deficiency were associated with significant reductions in systemic and lesional complement activation. Overall, our data provide the first direct evidence of the proatherogenic role of the amplification of complement activation by the alternative pathway in response to lipopolysaccharide or high-fat diet. This work lends support for developing therapeutic strategies aiming to inhibit the complement system by blocking the alternative pathway without interfering with the protective effect(s) mediated by the classical and lectin pathways.
Conclusions: These data demonstrate that amplification of complement activation by the alternative pathway in response to lipopolysaccharide or high-fat diet plays a proatherogenic role. 25 
Inhibiting Mitochondrial Fission Protects the Heart Against Ischemia/Reperfusion Injury
Summary: Despite optimal therapy, clinical outcomes in patients with coronary heart disease can be further improved by the discovery of new therapeutic strategies for protecting the heart from ischemia/ reperfusion injury. In this respect, in the present study, we have demonstrated that the modulation of mitochondrial morphology in the heart may provide a novel therapeutic strategy for cardioprotection. Specifically, we have demonstrated that inhibiting mitochondrial fission protected the heart by inhibiting the opening of the mitochondrial permeability transition pore, a critical mediator of ischemia/reperfusion injury. As a cardioprotective strategy, inhibition of mitochondrial fission may be induced through the pharmacological manipulation of mitochondrial morphology. In the present study, the in vivo pharmacological inhibition of the mitochondrial fission protein dynamin-related protein 1 with the small molecule inhibitor mdivi-1 reduced myocardial infarct size in the adult murine heart. The discovery of other novel compounds capable of inhibiting mitochondrial fission proteins such as dynamin-related protein 1 or activating mitochondrial fusion proteins such as mitofusin 1, mitofusin 2 or optic atrophy protein 1 may in the future be used to block mitochondrial fission in the clinical settings of acute ischemia/ reperfusion injury to reduce myocardial injury and infarct size in patients undergoing cardiac bypass surgery or patients presenting with a myocardial infarction, respectively, and to improve clinical outcomes in patients with coronary heart disease.
Conclusion:
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury, suggesting a novel pharmacological strategy for cardioprotection. 26 
Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice
Summary: Anthracyclines such as doxorubicin are effective chemotherapeutic agents used for treatment of many cancers. Unfortunately, their clinical use is limited by the risk of severe cardiotoxicity and heart failure that may not manifest until years later. Anthracyclines are of special concern in pediatric oncology because the youngest children are at the greatest risk of developing late-onset cardiotoxicity. In this study, we present the first evidence that anthracycline exposure in juvenile mice reduces the size of the cardiac progenitor pool, impairs their ability to differentiate into cells of cardiac and vascular lineages, and adversely affects vascular development in the heart. Despite normal development and hemodynamic function as adults, these mice develop rapid heart failure in response to physiological or pathological stress. This animal model recapitulates many of the features of late-onset anthracycline toxicity in humans and explains why younger children, who have more dividing progenitor cells, are more vulnerable. Our findings suggest that anthracycline-mediated effects on the progenitor cells might underlie the reduced ability to accomplish physiological hypertrophy as well as cardiac repair and neovascularization. Injection of stem cell mobilizing factors has been shown to enhance migration of bone Conclusions: Our data suggest that anthracycline treatment impairs vascular development as well as progenitor cell function in the young heart, resulting in an adult heart that is more susceptible to stress. 27
Int6/eIF3e Silencing Promotes Functional Blood Vessel Outgrowth and Enhances Wound Healing by Upregulating Hypoxia-Induced Factor 2␣ Expression
Summary: During the past decades, several studies have tried to trigger revascularization by exogenously applying angiogenic factors into the tissues of interest. A common obstacle was that the application of the specific angiogenic factor alone or an unbalanced combination with others led to the development of unphysiological and incomplete leaky blood vessels. In our research, we first found that hypoxia-inducible factor 2␣ is under subtype-specific and negative regulation of INT6, which directly binds to hypoxiainducible factor 2␣ and triggers its degradation through the proteasome pathway. Further in vivo experiments revealed that Int6 silencing led to enhancement of hypoxia-inducible factor 2␣ activity even under normoxic condition, temporarily inducing a physiological and potent neovascularization. In mouse skin, we determined subcutaneous fibroblasts as the major source of angiogenic factors. The fibroblasts treated ex vivo with siRNA-Int6 demonstrated that transplantation into the skin also led to the same strong induction of physiological neovascularization. Further application of siRNA-Int6 in a wound healing model (normal and db/db mice) showed a significantly enhanced wound repair with concomitant formation of new vessels. These results prefigure an encouraging therapeutic value of siRNA-Int6 for treating delayed wound healing, especially in diabetic patients with impaired microcirculation. Therefore, siRNA-Int6 -transfected fibroblast cell treatment or direct application of siRNA-Int6 might be of clinical value in treating ischemic diseases such as heart and brain ischemia, skin injury, and diseases involving obstructed vessels.
Conclusions:
We suggest that the pathway involving INT6/HIF2␣ acts as a hypoxia-independent master switch of functional angiogenesis; therefore, siRNA-Int6 application might be of clinical value in treating ischemic diseases such as heart and brain ischemia, skin injury, and diseases involving obstructed vessels. 28
Role of Pyruvate Dehydrogenase Inhibition in the Development of Hypertrophy in the Hyperthyroid Rat Heart: A Combined Magnetic Resonance Imaging and Hyperpolarized Magnetic Resonance Spectroscopy Study
Summary: The primary clinical significance of this article lies in the importance of gaining a better understanding of the underlying mechanisms resulting from hyperthyroidism. Using both noninvasive and novel techniques, we have thoroughly characterized the relationship between the metabolic and functional consequences of hyperthyroidism. By studying the metabolic perturbations associated with hyperthyroidism and using this information to devise a treatment regimen to improve metabolic flexibility in the hyperthyroid heart, we have uniquely shown that the associated cardiac hypertrophy can be reduced. We have also found that under conditions of plentiful energy supply, the heart is able to alter its response to maintain cardiac output. These findings are undoubtedly important, not only for this disease but also for other metabolic diseases affecting the heart. Furthermore, the potential to study the metabolic effects of hyperthyroidism and other cardiovascular diseases in humans with the hyperpolarized techniques presented here is clear. The first trials in humans with hyperpolarized pyruvate as a metabolic biomarker are imminent and offer many advantages over other forms of metabolic assessment such as including no radiation exposure and being a minimally invasive procedure. Metabolic studies with this technology can be integrated into existing MRI assessments of cardiac structure and function, as demonstrated here with a combined cine MRI and hyperpolarized magnetic resonance spectroscopy assessment.
Conclusions: This work has demonstrated that inhibition of glucose oxidation in the hyperthyroid heart in vivo is mediated by pyruvate dehydrogenase kinase. Relieving this inhibition can increase the metabolic flexibility of the hyperthyroid heart and reduce the level of hypertrophy that develops while maintaining the increased cardiac output required to meet the higher systemic metabolic demand. 29
CD69 Limits the Severity of Cardiomyopathy After Autoimmune Myocarditis
Summary: The mechanisms involved in the immune activation observed during the progression of human chronic heart failure and dilated cardiomyopathy have not been fully elucidated. However, a number of recent studies suggest that, besides genetic susceptibility and infections, chronic immune-mediated inflammation after acute myocarditis may lead to dilated cardiomyopathy. This report investigates the role of the leukocyte activation antigen CD69 in the modulation of the inflammatory response in a mouse model of autoimmune myocarditis. Our data demonstrate that CD69, through the regulation of Th17 effector responses, limits myocardial inflammation and subsequent heart failure. It is very feasible that a similar phenomenon occurs in humans with myocarditis and subsequent dilated cardiomyopathy. These findings reveal the involvement of a novel molecular actor in the immunopathogenesis of myocarditis, which could be a potential therapeutic target.
Conclusion:
Our findings indicate that CD69 negatively regulates heart-specific Th17 responses, cardiac inflammation, and heart failure progression in experimental autoimmune myocarditis. 30 
Wnt Signaling Mediates Pathological Vascular Growth in Proliferative Retinopathy
Summary: Pathological neovascularization in ischemic proliferative retinopathies such as retinopathy of prematurity and diabetic retinopathy is a major cause of blindness in children and working-age adults. Although anti-vascular endothelial growth factor therapy has been proven partially successful in the suppression of neovascularization, identification of other signaling mechanisms involved in this disease process is essential for developing therapies specifically targeting pathological vessels while sparing normal vessels. Here, we found that the Wnt signaling pathway, a pathway important for cardiac development and differentiation, is a major component in regulating pathological neovascularization in retinopathy. Using a mouse model of oxygen-induced retinopathy, we found that Wnt ligands and receptors are highly upregulated in retinas with induced retinopathy and pathological neovessels, respectively. Mutant mice lacking Wnt coreceptor Lrp5 or downstream signaling molecule dishevelled2 have significantly decreased levels of neovascularization. Importantly, the proangiogenic effect of Wnt signaling is mediated through tight junction protein claudin5, which is highly downregulated in Lrp5-null vessels. Suppression of claudin5 significantly inhibits Wnt-mediated vascular growth in vitro and pathological vessel growth in vivo. Our data suggest that Wnt signaling pathway plays a significant role in mediating pathological vascular growth in ischemic proliferative retinopathy, and selectively targeting this pathway might be a potentially useful strategy to develop future therapies for retinopathy.
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Conclusions: These results demonstrate an important role of Wnt signaling in pathological vascular development in retinopathy and show a novel function of Cln5 in promoting angiogenesis. 31
Protease-Resistant Stromal Cell-Derived Factor-1 for the Treatment of Experimental Peripheral Artery Disease
Summary: Peripheral artery disease is a common disorder that is associated with significant morbidity. Peripheral artery disease can present as chronic ischemia with claudication or as critical limb ischemia. Traditional treatment of peripheral artery disease includes vascular surgery; however, few patients can be treated successfully with surgery only. There is a need for new drugs and delivery systems because few drug therapies for peripheral artery disease currently exist. A potential candidate treatment for treatment of peripheral artery disease would be injection of stromal cell-derived factor-1 (SDF-1), a protein that attracts angiogenic progenitor cells. However, SDF-1 is rapidly degraded by proteases expressed in ischemic tissues. Therefore, we designed novel variants of SDF-1 that are protease resistant. In the present study, we show that protease-resistant SDF-1, called SSDF-1(S4V), induces formation of new blood vessels in a mouse model of peripheral artery disease. SSDF-1(S4V) only induces arteriogenesis when delivered in a hydrogel of self-assembling peptides, indicating that slow release is necessary for functional improvement. On the basis of this study, we believe that SSDF-1(S4V), when injected locally in patients with peripheral artery disease, can result in formation of new vessels and increased tissue perfusion. Local delivery of SSDF-1(S4V) might improve quality of life in patients with peripheral artery disease.
Conclusions: SDF-1 engineered to be resistant to dipeptidylpeptidase IV/CD26 and matrix metalloproteinase-2 cleavage and delivered by nanofibers improves blood flow in a model of peripheral artery disease. 32
Tumor Necrosis Factor Receptor-Associated Factor 1 (TRAF1) Deficiency Attenuates Atherosclerosis in Mice by Impairing Monocyte Recruitment to the Vessel Wall
Summary: Tumor necrosis factor receptor-associated factors (TRAFs) mediate inflammatory signaling for important cytokines of the tumor necrosis factor/interleukin-1/Toll-like receptor superfamily such as CD40L, tumor necrosis factor-␣, and interleukin-1␤. Atherosclerosis is a chronic inflammatory disease governed by a network of such inflammatory cytokines. Although the inflammatory nature of atherosclerosis has been known for some time, cardiology still lacks a causal anti-inflammatory or immunomodulatory treatment option. The potential of such therapies is clearly suggested by the pleiotropic treatment benefits of statins, most recently demonstrated in the JUPITER trial (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
Although overall inhibition of cytokines may produce a variety of undesirable side effects, the inhibition of specific signaling intermediates potentially may overcome some of these limitations. The present study presents the novel and somewhat unexpected finding that TRAF1 deficiency potently attenuates murine atherosclerosis, most likely by impairing monocyte recruitment to the vessel wall, which suggests a proatherogenic function of TRAF1. In line with this notion, we found increased expression of TRAF1 in blood of patients who had an acute coronary syndrome. Future studies will be needed to determine whether TRAF1 targeting might indeed represent a novel treatment strategy for chronic inflammatory diseases such as atherosclerosis.
Conclusions: TRAF1 deficiency attenuates atherogenesis in mice, most likely owing to impaired monocyte recruitment to the vessel wall. These data identify TRAF1 as a potential treatment target for atherosclerosis. 33 
Human Cardiac Stem Cell Differentiation Is Regulated by a Mircrine Mechanism
Summary: Effective repair of the damaged heart requires the recovery of the normal architecture and function of the organ. Myocardial regeneration mediated by activation and differentiation of human cardiac stem cells commonly results in the formation of small myocytes with fetal-neonatal characteristics. The number of new cells exceeds the number of myocytes lost, but the replacement of cardiac mass is incomplete because the regenerated myocytes fail to acquire the adult phenotype. This limitation in myocyte maturation has been partly overcome by enhancing the expression of microRNA-499 in human cardiac stem cells; microRNA-499 represses genes responsible for the primitive state of these cells, promoting the program of myocyte differentiation, structurally and functionally. In the presence of microRNA-499, the regenerated parenchymal cells increase in size and acquire electric and mechanical properties of adult cells. This process occurs by the physiological translocation of microRNA-499 from myocytes to human cardiac stem cells via gap junction channels. Importantly, the potentiated reconstitution of the infarcted myocardium has significant effects on the anatomic remodeling and hemodynamic performance of the injured heart. Understanding the molecular control that regulates the differentiation of human cardiac stem cells into functionally competent cardiomyocytes may be critical for the implementation of stem cell therapy in the diseased heart.
Conclusions:
The recognition that miR-499 promotes the differentiation of hCSCs into mechanically integrated cardiomyocytes has important clinical implications for the treatment of human heart failure. 34
Regulatory T Cells Protect Mice Against Coxsackievirus-Induced Myocarditis Through the Transforming Growth Factor ␤-Coxsackie-Adenovirus Receptor Pathway
Summary: Currently, the standard of care from acute myocarditis remains hemodynamic and cardiovascular support, including the use of a heart failure drug regimen, ventricular assist devices, and transplantation when necessary. Coxsackievirus B3 infections have been shown to cause acute or chronic myocarditis and dilated cardiomyopathy. Cardiac injury is caused by a direct cytopathic effect of the virus, the immune response to viral infection, or autoimmunity triggered by viral infection. A modulation strategy that processes the antiviral immunity without excessive autoimmune tissue injury would be beneficial in treating coxsackievirus B3-associated autoimmune myocarditis. Suppressor T cells, now renamed regulatory T cells (Tregs), are important negative immune modulators and constitute 5% to 10% of peripheral CD4 ϩ T cells in naïve mice and humans. Strategies to increase Treg population or direct Tregs therapy have begun to be tested in cardiovascular diseases, including atherosclerosis, allograft rejection, and diabetes mellitus. In this study, we evaluated the potential protective effects of Tregs in a myocarditis model by transferring naturally occurring Tregs to mice before infection with coxsackievirus B3. Surprisingly, the adoptive transfer of Tregs not only attenuated the excessive inflammatory response to coxsackievirus B3 but also facilitated viral clearing in heart tissue through the transforming growth factor ␤-coxsackie-adenovirus receptor pathway. These results suggest that immune-modulating therapies can potentially improve the outcome in viral myocarditis. In the future, manipulating Tregs through small molecules or biological agents may provide a novel therapeutic strategy for viral myocarditis or other inflammatory processes causing cardiovascular complications.
Conclusions: Adoptive transfer of Tregs protected mice from coxsackievirus B3-induced myocarditis through the transforming growth factor ␤-coxsackie-adenovirus receptor pathway and thus suppresses the immune response to cardiac tissue, maintaining the antiviral immune response. 35 
Peroxisome Proliferator-Activated Receptor-␥ Agonists Prevent In Vivo Remodeling of Human Artery Induced by Alloreactive T Cells
Summary: Human allograft rejection differs from that which occurs in rodent models owing to differences in the immune properties of graft cells, especially of endothelial cells, and to the presence in humans of memory T cells that can respond to and reject an allograft. Consequently, therapies that work in rodents often fail in humans. Peroxisome proliferator-activated receptor-␥ agonists, in addition to their role in lipid metabolism, can suppress inflammation and immunity. We show in this study that these agents can suppress the responses of human memory T cells to allogeneic blood vessels in vivo and to allogeneic endothelial cells in vitro. These data suggest the possibility that peroxisome proliferator-activated receptor-␥ agonists could have benefit in clinical transplantation.
Conclusion:
Our results suggest that PPAR␥ agonists inhibit allogeneic human memory T cell responses and may be useful for the treatment of vascular graft rejection. 36 
Intrinsic Cardiac Nerve Activity and Paroxysmal Atrial Tachyarrhythmia in Ambulatory Dogs
Summary: Cardiac innervation is derived from both extrinsic and intrinsic sources. These 2 sources of innervation jointly control cardiac function, including heart rhythm and arrhythmogenesis. The intrinsic nerves form ganglionated plexi, which are concentrated in the epicardial fat pads. The present study is aimed at developing a method to record intrinsic cardiac nerve activities in ambulatory dogs and to correlate these nerve activities with the spontaneous onset of paroxysmal atrial tachyarrhythmias. We found that it is feasible to record intrinsic cardiac nerve activities from the fat pads in ambulatory dogs and that these nerve activities invariably precede the onset of paroxysmal atrial tachycardia and atrial fibrillation. These findings may explain the results of recent clinical studies that show that radiofrequency catheter ablation aimed at ganglionated plexi improves the long-term outcome of atrial fibrillation ablation. Our findings may also lead to a more comprehensive strategy in developing antiarrhythmic drugs for paroxysmal atrial tachyarrhythmias. The existing antiarrhythmic drugs are developed to target the action potential or calcium handling characteristics of the myocardial cells. The antiarrhythmic efficacy of the existing drugs in treating paroxysmal atrial tachyarrhythmias is limited. The results of the present study suggest that intrinsic cardiac nerve activities may be the triggers of these arrhythmias. If so, then drugs designed to suppress the intrinsic cardiac nerve activity may provide additional benefit to atrial arrhythmia control.
Conclusions: There is a significant temporal relationship between extrinsic cardiac nerve activity (ECNA) and intrinsic cardiac nerve activity (ICNA). However, ICNA can also activate alone. All paroxysmal atrial tachycardia and atrial fibrillation episodes were invariably preceded by ICNA. These findings suggest that ICNA (either alone or in collaboration with ECNA) is an invariable trigger of paroxysmal atrial tachyarrhythmias. ICNA might contaminate local atrial electrograms, resulting in complex fractionated atrial electrogram-like activity. 37 
Complement Regulator CD59 Protects Against Angiotensin II-Induced Abdominal Aortic Aneurysms in Mice
Summary: Aneurysm, including abdominal aortic aneurysm (AAA), is considered an immune and inflammatory disease. Complement is a main effector of the immune response and inflammation. However, the role of complement in the aneurysm pathogenesis has not been extensively investigated. The complement system is activated by 3 activation cascades, which lead to formation of the membrane attack complex (MAC). MAC, a macromolecular pore capable of inserting itself into cell membranes and lysing heterologous cells and bacteria, is an important mediator of cellular signals, including nuclear factor-B and activator protein-1, which trigger mitogenic effects. To protect autologous cells from MAC, an array of complement regulators, including CD59, have evolved to restrict complement activation. CD59 strongly restricts MAC formation. Here, we demonstrated that in the angiotensin-induced abdominal aortic aneurysm model, deficiency of CD59 in ApoE-null mice accelerated the abdominal aortic aneurysm development, whereas transgenic overexpression of CD59 attenuated the abdominal aortic aneurysm progression. The severity of aneurysm positively correlates with C9 deposition, the activities of matrix metalloproteinase-2 and -9, and the levels of phosphorylated c-Jun, c-Fos, IKK-␣/␤, and p65. Furthermore, we demonstrated that MAC directly induced gene expression of matrix metalloproteinase-2 and -9 in vitro, which depended on the activation of the activator protein-1 and nuclear factor-B signaling pathways. Together, these results shed light on the important pathogenic role of MAC in aneurysm, point toward the molecular mechanism of MAC-activated signaling pathways in aneurysm, and suggest that inhibition of MAC may provide a novel approach for the treatment/prevention of aneurysm.
Conclusion:
Together, these results defined the protective role of CD59 and shed light on the important pathogenic role of the membrane attack complex in abdominal aortic aneurysm. 38 
Adipocyte Modulation of High-Density Lipoprotein Cholesterol
Summary: Adipose tissue harbors a major pool of free cholesterol, but its role in regulating circulating high-density lipoprotein (HDL) cholesterol is poorly understood. In this work, we present the first evidence that adipocytes transfer cholesterol to HDL in vivo as well as in vitro. We identified a differentiation-dependent role for the lipid transporters ATP-binding cassette subfamily A member 1 and scavenger receptor class B type I, but not ATP-binding cassette subfamily G member 1, in adipocyte cholesterol efflux to apolipoprotein A-I and mature HDL, respectively. We also provide experimental evidence that both ATP-binding cassette subfamily A member 1 and scavenger receptor class B type I can regulate adipocyte cholesterol transfer to HDL in vivo. Finally, we show that adipocyte inflammation downregulates transporters and impairs adipocyte cholesterol efflux to HDL. Our findings suggest a role for mature adipose in directly maintaining HDL cholesterol levels. Conversely, adipose inflammation may attenuate adipocyte lipidation of HDL and may directly contribute to lower HDL cholesterol in adipose inflammatory states such as central obesity and type 2 diabetes mellitus. Thus, adipose tissue cholesterol homeostasis may be a direct therapeutic target for modulation of HDL levels in vivo.
Conclusions: These data suggest a novel metabolic function of adipocytes in promoting cholesterol transfer to HDL in vivo and implicate adipocyte scavenger receptor class B type I and ATP-binding cassette subfamily A member 1 but not ATP-binding cassette subfamily G member 1 in this process. Furthermore, adipocyte modulation of HDL may be impaired in adipose inflammatory disease states such as type 2 diabetes mellitus. 39 
Inhibition of Hyaluronan Synthesis Accelerates Murine Atherosclerosis: Novel Insights Into the Role of Hyaluronan Synthesis
Summary: Hyaluronan is an integral extracellular matrix component that plays crucial roles in, for example, development and homeostasis of cartilage and skin. However, increased hyaluronan production is associated with tumor progression and vascular disease. Hyaluronan accumulates during neointimal thickening in atherosclerotic plaques and restenotic lesions. In the neointima, it contributes to
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volume expansion and supports the proliferative and secretory phenotype of vascular smooth muscle cells. Therefore, inhibition of hyaluronan synthesis has been considered as a strategy to limit neointimal thickening and atheroprogression. On the other hand, recent research has established hyaluronan on the luminal surface of vascular endothelial cells to be a critical constituent of the endothelial glycocalyx, which has strong vasoprotective functions. In the present study, it is shown in a murine model of atherosclerosis that inhibition of hyaluronan synthesis by an oral hyaluronan synthesis inhibitor surprisingly enhances inflammatory and thrombotic responses and in the long term increases atherosclerosis. This adverse effect was attributed to a partial loss of the endothelial glycocalyx. Of note, hyaluronan synthesis inhibitors are effective in inhibiting tumor progression in mouse models and may be tested clinically to enhance the response to antitumor strategies. In light of the present results, it may be crucial to avoid adverse effects on the endothelial glycocalyx because damage of the glycocalyx may lead to increased atherothrombotic risk and enhance inflammatory cell recruitment.
Conclusions:
The data suggest that systemic inhibition of hyaluronan synthesis by 4-methylumbelliferone interferes with the protective function of the endothelial glycocalyx, thereby facilitating leukocyte adhesion, subsequent inflammation, and progression of atherosclerosis. 40
Molecular Magnetic Resonance Imaging of Myocardial Angiogenesis After Acute Myocardial Infarction
Summary: Angiogenesis is a natural relief mechanism to restore perfusion to ischemic myocardium after acute myocardial infarction. Therapeutic angiogenesis is being explored as a novel treatment option for myocardial infarction patients; however, sensitive, noninvasive in vivo measures of therapeutic efficacy are lacking and need to be developed. Here, a molecular MRI method is presented to noninvasively image angiogenic activity in vivo in a murine model of myocardial infarction with a targeted, bimodal (ie, paramagnetic and fluorescent) contrast agent. Intravenous injection of the contrast agent resulted in a strong increase in image contrast in the infarcted myocardium. Significantly less change in image contrast was found in myocardial infarction mice injected with a control contrast agent or in sham-operated mice injected with the targeted agent. The MRI results were confirmed by ex vivo fluorescence microscopy, which also demonstrated significant microvascular remodeling in the infarction and border zones of the heart in response to myocardial infarction. Future clinical applications of the presented molecular MRI method include early noninvasive evaluation of proangiogenic therapy, prediction of improvements in myocardial perfusion and function based on the early angiogenic response, risk stratification, development of individualized therapy, and monitoring of drug delivery.
Conclusions: Cyclic Asn-Gly-Arg (cNGR)-labeled paramagnetic quantum dots (pQDs) allow selective, noninvasive detection of angiogenic activity in the infarcted heart with the use of in vivo molecular MRI and ex vivo 2-photon laser scanning microscopy. 41 
Atrial Sources of Reactive Oxygen Species Vary With the Duration and Substrate of Atrial Fibrillation: Implications for the Antiarrhythmic Effect of Statins
Summary: Atrial fibrillation (AF) is a very common arrhythmia, and its therapy remains a challenge. There is considerable interest in developing treatment strategies that target mechanisms upstream of ion channel modifications; however, whereas ion channel modifications are the common denominator of virtually all types of AF, the myocardial signaling upstream of atrial electric and structural remodeling differs with the stage and substrate of AF, demanding a more refined ad hoc approach to the prevention and management of this arrhythmia. Here, we show that the mechanisms responsible for the nitric oxide-redox imbalance in the fibrillating atrial myocardium change with the duration of AF and the development of atrial structural remodeling. Upregulation of atrial NOX2 activity and expression is an early but transient event in the natural history of AF and may be causally linked to both new-onset AF and early AF-induced atrial remodeling. Once AF becomes established and atrial structural remodeling ensues, the oxidase systems underlying the increase in reactive oxygen species shift from NOX2 to mitochondrial oxidases and uncoupled nitric oxide synthases. Ex vivo atorvastatin induces a mevalonate-reversible inhibition of atrial Rac1 and NOX2 activity in patients who developed AF after cardiac surgery, but it does not affect atrial reactive oxygen species production and nitric oxide synthase activity in patients with permanent AF. These findings imply that NOX2 inhibition by drugs such as statins may be effective only in preventing new-onset AF or early AFinduced electric remodeling of the atrial myocardium.
Conclusions: Upregulation of atrial NADPH oxidases is an early but transient event in the natural history of AF. Changes in the sources of reactive oxygen species with atrial remodeling may explain why statins are effective in the primary prevention of AF but not in its management. 42
Endothelial-Specific Deletion of Connexin40 Promotes Atherosclerosis by Increasing CD73-Dependent Leukocyte Adhesion
Summary: Endothelial dysfunction, the initiating event of atherosclerosis, is characterized by increased expression of adhesion molecules and cytokines, which promotes the transmigration of leukocytes into the atherosclerotic lesion. This study provides evidence that connexin40 (Cx40), a gap junction protein expressed in endothelial cells, regulates the activity of the membrane-bound 5Ј-ecto-nucleotidase (CD73). The activity of endothelial CD73 generates adenosine from the hydrolysis of adenine nucleotides. Adenosine, in turn, activates surface membrane receptors to trigger antiadhesion signals for leukocytes to the endothelium. We have generated an atherosclerosis-susceptible mouse line in which Cx40 is specifically deleted from the endothelium. Endothelial deletion of Cx40 accelerated atherosclerotic lesion formation and coincided with increased expression of vascular cell adhesion molecule-1 as well as decreased expression of CD73. The antiadhesive role of Cx40 was confirmed in an endothelial cell line by specific targeting of Cx40 with antisense and small interfering RNA. We also found that functional Cx40 intercellular channels convey antiadhesion signals for leukocytes. Thus, Cx40-dependent regulation of CD73 may contribute to the spatial propagation of anti-inflammatory and antiadhesive responses within the endothelium. These findings provide a molecular basis for therapeutic modulation of Cx40-mediated intercellular communication, which may be beneficial not only in atherosclerosis but for other inflammatory diseases as well. Of note, Cx40 gene polymorphisms affecting protein expression levels have been associated recently with hypertension in humans. Future investigations should determine whether these polymorphisms might be of use in atherosclerosis risk assessment.
Conclusions: Cx40-mediated gap junctional communication contributes to a quiescent nonactivated endothelium by propagating adenosineevoked anti-inflammatory signals between endothelial cells. Alteration in this mechanism by targeting Cx40 promotes leukocyte adhesion to the endothelium, thus accelerating atherosclerosis. 43 
Late Sodium Current Contributes to the Reverse Rate-Dependent Effect of I Kr Inhibition on Ventricular Repolarization
Summary: The reverse rate-dependent effect of drugs, especially those that inhibit I Kr to prolong ventricular repolarization, has long been recognized as an important proarrhythmic risk factor. We hypothesize that inhibition of the small physiological late Na ϩ current (late I Na ) will reduce reverse rate dependence associated with I Kr -blocking drugs. Late I Na is greater, and reverse rate dependence of APD/QT interval is prominent in patients with structural heart diseases (heart failure, myocardial ischemia, etc), especially after treatment with an I Krinhibiting drug. In this study, the amplitude of endogenous or physiological late I Na in myocytes was increased as the frequency of stimulation slowed. Inhibition of late I Na by tetrodotoxin or ranolazine diminished the reverse rate dependence of action potential duration prolongation and beat-to-beat variability of repolarization caused by I Kr inhibitors in isolated hearts. Results of computer simulations of the effect of I Kr block in the absence and presence of late I Na block were consistent with the results of the experimental studies. The findings can explain, at least in part, why drugs that inhibit both I Kr and late I Na (ie, amiodarone and ranolazine) have no reverse rate-dependent effect and little or no proarrhythmic activity, whereas proarrhythmic activity associated with more selective I Kr blockers is exacerbated when late I Na is increased. This concept may be used to explain the occurrence of slow rate-or pause-triggered cardiac arrhythmias, and may be relevant in the choice of treatment drug(s) in patients with compromised repolarization reserve resulting from increased late I Na or decreased I K , such as patients with heart failure.
Conclusion:
Endogenous late I Na contributes to the reverse ratedependence of I Kr inhibitor-induced increases in action potential duration and beat-to-beat variability of repolarization and to bradycardia-related ventricular arrhythmias. 44 
Genetic and Pharmacological Hydrogen Sulfide Therapy Attenuates Ischemia-Induced Heart Failure in Mice
Summary: Heart failure continues to be a major health problem as evidenced by a rise in the number of hospitalizations for heart failure, the number of deaths attributed to heart failure, and the ever-increasing costs associated with care. Therapeutic strategies designed to coincide with the standard means of care are, therefore, needed to combat the development and progression of heart failure. Hydrogen sulfide (H 2 S) is an endogenous gaseous signaling molecule with a diverse physiological profile that has recently been shown to be cardioprotective in various models of cardiac injury. In the present study, we found that either the modulation of endogenous H 2 S production or direct pharmacological H 2 S administration significantly reduced mortality and attenuated the severity of ischemiainduced heart failure in mice. Importantly, the present study demonstrates that although a single administration of H 2 S at the time of reperfusion is beneficial in attenuating infarct size, this alone is not sufficient to improve cardiac function significantly. On the other hand, daily H 2 S therapy for the first 7 days of reperfusion or increased endogenous H 2 S production provided significant improvements in cardiac function, suggesting that multiple therapeutic interventions are paramount for improvements in outcome. Together, these findings further support the emerging concept that H 2 S therapy may be of clinical importance in the treatment of cardiovascular disease and may have a practical clinical use after myocardial infarction to reduce the morbidity and mortality associated with ischemia-induced heart failure.
Conclusions:
The results of the present study suggest that either the administration of exogenous H 2 S or the modulation of endogenous H 2 S production may be of therapeutic benefit in the treatment of ischemia-induced heart failure. 45 
Matricellular Signaling Molecule CCN1 Attenuates Experimental Autoimmune Myocarditis by Acting as a Novel Immune Cell Migration Modulator
Summary: CCN1 is an evolutionary ancient matricellular protein that modulates biological processes associated with tissue repair. Here, we provide evidence of a novel function of CCN1 as a modulator of immune cell migration, with therapeutic potential in diseases associated with chronic pathogenic inflammation. In the current proof-of-concept study, we used CCN1 gene transfer to evaluate its therapeutic potential in animal models of human inflammatory cardiomyopathy and myocardial infarction. CCN1 therapy significantly reduced immune cell infiltration in both models. CCN1 exposure resulted in strongly suppressed migration of immune cells both in vivo and in vitro and abrogated their chemotactic response to various chemokines. These data suggest that CCN1 has potential as a new broad-spectrum immune cell migration inhibitor, in contrast to specific chemokine-or chemokine receptor-blocking agents with their known limitations arising from the fact that in most inflammatory diseases, multiple chemokines and chemokine receptors are involved and no single target of outstanding pathogenic importance exists. From a clinical translational perspective, it is of interest that the effects of the endogenous protein CCN1 on immune cell chemotaxis and migration are partially mimicked by cyclic RGD peptides that are currently being evaluated in clinical trials, although as yet for cancer therapy only. Our proof-of-concept study suggests further investigation of CCN1 as a new parent compound for immune cell migration modulation and of cyclic RGD peptides as CCN1 mimetics with immediate potential for clinical evaluation in cardiac diseases associated with chronic pathogenic inflammation.
Conclusions: Our proof-of-concept study suggests investigation of CCN1 as a novel, endogenous "parent compound" for chemotaxis modulation and of cyclic RGD peptides as a class of partially CCN1-mimetic drugs with immediate potential for clinical evaluation in cardiac diseases associated with chronic pathogenic inflammation. 46 
